Search
forLearn
5 / 801 resultslearn Selenium sulfide
learn Copper Peptides
learn pyrithione
learn molybdenum
Research
5 / 286 results
research Palladium nanoparticles on a pyridinium supported ionic liquid phase: a recyclable and low-leaching palladium catalyst for aminocarbonylation reactions
The new palladium catalyst is effective and reusable for making pharmaceutical ingredients.
research Bioorthogonal Catalytic Microneedles Based on a Cytotoxic PEI Matrix for Synergistic Melanoma Therapy
A new microneedle patch significantly improves melanoma treatment by using a special material to activate cancer-fighting drugs and disrupt cancer cells.
research Recommended Articles
New technologies in acupuncture and biosensors show promise for better medical treatments and healing.
research The promoted synthesis of minoxidil by magnetic nanoparticles of cobalt ferrite(CoFe2O4) as a heterogeneous reusable catalyst
Researchers made minoxidil efficiently using cobalt ferrite nanoparticles as a reusable catalyst.
research The effects of particle properties on nanoparticle drug retention and release in dynamic minoxidil foams
Particle properties affect drug retention and release in minoxidil foams, with lipid nanoparticles having higher loading capacity.
Community Join
5 / 1000+ resultscommunity 18m, already balding. Is a hair system the way to go? I don’t have the strength to go bald this young
An 18-year-old with early hair loss is advised to consider minoxidil and finasteride, with a doctor's consultation recommended. Alternatives like a hair system or shaving are suggested due to potential medication side effects and lifelong commitment.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
community Oral PTD-DBM available online, worth giving a shot?
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.